现代背景下伯基特淋巴瘤:30家美国癌症中心的真实世界结局与预后分析
本研究纳入2009至2018年30家美国癌症中心的641例未经治疗的成人伯基特淋巴瘤患者,评估无进展生存期和总生存期相关因素。中位随访45个月,3年无进展生存率和总生存率分别为64%和70%,HIV状态无差异。多因素分析显示年龄≥40岁、ECOG体能状态2-4分、乳酸脱氢酶>3倍正常上限和中枢神经系统受累预测生存较差。
要点
- 接受利妥昔单抗者3年无进展生存率67% vs 未接受者38%,总生存率72% vs 44%,P<.001。
- 学术癌症中心3年无进展生存率67% vs 社区中心46%,P=.006;总生存率72% vs 53%,P=.01。
- 预后因素数目0、1、2-4个的3年无进展生存率分别为91%、73%、50%。
核心结论
- 该真实世界分析中成人伯基特淋巴瘤的结局似乎较临床试验和较小系列的结果更为温和。
- 诊断时的临床预后因素可识别出生存率差异明显的患者。
研究设计与样本
- 回顾性分析2009至2018年30家美国癌症中心641例未经治疗的成人伯基特淋巴瘤患者。
- 采用单因素和多因素Cox模型评估无进展生存期和总生存期的相关因素。
主要发现
- 中位年龄47岁,HIV阳性22%,ECOG体能状态2-4分23%,>1个结外部位43%,晚期78%,中枢神经系统受累19%。
- 治疗相关死亡率为10%,最常见原因为脓毒症、胃肠道出血/穿孔和呼吸衰竭。
- 中位随访45个月,3年无进展生存率和总生存率分别为64%和70%,HIV状态无差异。
- 接受利妥昔单抗者3年无进展生存率67% vs 未接受者38%,总生存率72% vs 44%,P<.001;给药场所(住院 vs 门诊)无差异。
- 学术癌症中心3年无进展生存率67% vs 社区癌症中心46%,P=.006;总生存率72% vs 53%,P=.01。
关键数值与推荐
- 多因素分析中年龄≥40岁:无进展生存期HR=1.70,P=.001;总生存期HR=2.09,P<.001。
- ECOG体能状态2-4分:无进展生存期HR=1.60,P<.001;总生存期HR=1.74,P=.003。
- 乳酸脱氢酶>3倍正常上限:无进展生存期HR=1.83,P<.001;总生存期HR=1.63,P=.009。
- 中枢神经系统受累:无进展生存期HR=1.52,P=.017;总生存期HR=1.67,P=.014。
- 预后因素数目0、1、2-4个:3年无进展生存率分别为91%、73%、50%;3年总生存率分别为95%、77%、56%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We examined adults with untreated Burkitt lymphoma (BL) from 2009 to 2018 across 30 US cancer centers. Factors associated with progression-free survival (PFS) and overall survival (OS) were evaluated in univariate and multivariate Cox models. Among 641 BL patients, baseline features included the following: median age, 47 years; HIV+, 22%; Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 to 4, 23%; >1 extranodal site, 43%; advanced stage, 78%; and central nervous system (CNS) involvement, 19%. Treatment-related mortality was 10%, with most common causes being sepsis, gastrointestinal bleed/perforation, and respiratory failure. With 45-month median follow-up, 3-year PFS and OS rates were 64% and 70%, respectively, without differences by HIV status. Survival was better for patients who received rituximab vs not (3-year PFS, 67% vs 38%; OS, 72% vs 44%; P < .001) and without difference based on setting of administration (ie, inpatient vs outpatient). Outcomes were also improved at an academic vs community cancer center (3-year PFS, 67% vs 46%, P = .006; OS, 72% vs 53%, P = .01). In multivariate models, age ≥ 40 years (PFS, hazard ratio [HR] = 1.70, P = .001; OS, HR = 2.09, P < .001), ECOG PS 2 to 4 (PFS, HR = 1.60, P < .001; OS, HR = 1.74, P = .003), lactate dehydrogenase > 3× normal (PFS, HR = 1.83, P < .001; OS, HR = 1.63, P = .009), and CNS involvement (PFS, HR = 1.52, P = .017; OS, HR = 1.67, P = .014) predicted inferior survival. Furthermore, survival varied based on number of factors present (0, 1, 2 to 4 factors) yielding 3-year PFS rates of 91%, 73%, and 50%, respectively; and 3-year OS rates of 95%, 77%, and 56%, respectively. Collectively, outcomes for adult BL in this real-world analysis appeared more modest compared with results of clinical trials and smaller series. In addition, clinical prognostic factors at diagnosis identified patients with divergent survival rates.
引用
- Evens AM, Danilov A, Jagadeesh D, et al. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. Blood. 2021. PMID: 32663292. doi:10.1182/blood.2020006926
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。